secwatch.observer — SEC 8-K summary
======================================

Issuer:     Guardant Health, Inc. (GH)
CIK:        0001576280
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001576280-23-000121
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Guardant Health Q2 revenue $137.2M (+26% YoY); raises FY2023 revenue guidance to $545-550M
--------------------------------------------------------------------------------

- Revenue $137.2M (+26% YoY); clinical test volume 43,500 (+49%), biopharma tests 6,700 (+12%).
- Net loss $72.8M vs $229.4M prior year (includes fair value changes); Non-GAAP net loss $88.7M.
- Raised FY2023 revenue guidance to $545-550M (from $535-545M); expects operating expenses below 2022 levels.
- Cash $1.2B; completed public offering raising $381M net; Guardant360 now covered by all major U.S. commercial insurers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576280/000157628023000121/0001576280-23-000121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576280/000157628023000121/gh-20230803.htm
  HTML page:      https://secwatch.observer/filing/0001576280-23-000121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer